Compare · LIVN vs POCI
LIVN vs POCI
Side-by-side comparison of LivaNova PLC (LIVN) and Precision Optics Corporation Inc. (POCI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LIVN and POCI operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- LIVN is the larger of the two at $4.49B, about 92.3x POCI ($48.7M).
- Over the past year, LIVN is up 92.2% and POCI is down 5.9% - LIVN leads by 98.1 points.
- LIVN has hit the wire 1 time in the past 4 weeks while POCI has been quiet.
- LIVN has more recent analyst coverage (20 ratings vs 0 for POCI).
- Company
- LivaNova PLC
- Precision Optics Corporation Inc.
- Price
- $81.74+2.93%
- $4.60-2.95%
- Market cap
- $4.49B
- $48.7M
- 1M return
- +2.57%
- -22.10%
- 1Y return
- +92.19%
- -5.93%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 1
- 0
- Recent ratings
- 20
- 0
LivaNova PLC
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients. It also provides surgical tissue and mechanical valve replacements, and repair products for damaged or diseased heart valves, such as self-anchoring tissue heart, tissue heart, and mechanical heart valves, as well as heart valve repair products; and temporary extracorporeal cardiopulmonary life support solutions for critically ill patients. The NM segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
Latest LIVN
- LivaNova to Announce Second-Quarter 2026 Results
- Director Wilver Peter M covered exercise/tax liability with 486 units of Ordinary Shares and converted options into 4,042 units of Ordinary Shares, increasing direct ownership by 53% to 10,294 units (SEC Form 4)
- Chief Innovation Officer Tezel Ahmet converted options into 2,965 units of Ordinary Shares and covered exercise/tax liability with 1,032 units of Ordinary Shares, increasing direct ownership by 46% to 6,090 units (SEC Form 4)
- Director Bianchi Francesco covered exercise/tax liability with 486 units of Ordinary Shares, sold $96,228 worth of Ordinary Shares (1,200 units at $80.19) and converted options into 4,042 units of Ordinary Shares, increasing direct ownership by 33% to 9,584 units (SEC Form 4)
- Director Podlogar Susan M converted options into 4,042 units of Ordinary Shares and covered exercise/tax liability with 486 units of Ordinary Shares, increasing direct ownership by 170% to 5,642 units (SEC Form 4)
- Director Schermerhorn Todd C converted options into 4,042 units of Ordinary Shares and covered exercise/tax liability with 486 units of Ordinary Shares, increasing direct ownership by 39% to 12,619 units (SEC Form 4)
- SEC Form 4 filed by Director Nygaard-Andersen Jette
- Director Enxing Seng Stacy converted options into 4,042 units of Ordinary Shares and covered exercise/tax liability with 486 units of Ordinary Shares, increasing direct ownership by 30% to 15,307 units (SEC Form 4)
- Director Kozy William A converted options into 5,681 units of Ordinary Shares and covered exercise/tax liability with 682 units of Ordinary Shares, increasing direct ownership by 15% to 37,566 units (SEC Form 4)
- Director Barry James Christopher covered exercise/tax liability with 486 units of Ordinary Shares and converted options into 4,042 units of Ordinary Shares, increasing direct ownership by 82% to 7,918 units (SEC Form 4)
Latest POCI
- Precision Optics to Present at the Planet MicroCap Las Vegas 2026 Investor Conference on June 17, 2026
- Precision Optics to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
- Precision Optics Reports Third Quarter Fiscal Year 2026 Financial Results
- SEC Form 10-Q filed by Precision Optics Corporation Inc.
- New insider Needham Investment Management Llc claimed ownership of 3,341,100 shares (SEC Form 3)
- Precision Optics Schedules Third Quarter of Fiscal Year 2026 Conference Call for May 13, 2026
- Precision Optics Announces Receipt of $3.5 Million Follow-On Production Order for Single-Use Ophthalmic Program
- SEC Form 3 filed by new insider Needham Investment Management Llc
- SEC Form 4 filed by Coll Wayne M
- SEC Form 4 filed by Traut Joseph